Integral Molecular Celebrates 25 Years of Advancing Drug Discovery as a Cornerstone of Philadelphia's Biotech Community

PHILADELPHIA, Nov. 12, 2026 /PRNewswire/ -- Integral Molecular, a founding member of Philadelphia's biotechnology community, celebrates its 25th anniversary by bringing together its expertise in antibody discovery, protein engineering, and specificity testing to build a broad pipeline of therapeutic antibodies for cancer and other diseases.

"We started Integral Molecular to solve scientific problems that were holding back drug discovery against membrane proteins implicated in some of the hardest-to-treat diseases," said Benjamin Doranz, PhD, co-founder and CEO of Integral Molecular. "Over 25 years, we've built the tools and expertise to tackle increasingly challenging targets. What excites us now is putting those capabilities together to discover potential new medicines against targets that have long been out of reach."

Learn more about Integral Molecular's technologies and partnership opportunities

Unlocking the Next Generation of Drug Targets

Because of complex biology and the lack of validated research reagents, many human proteins remain largely unexplored as drug targets, despite strong evidence linking them to disease. To advance antibody drug discovery and development against these targets, the company is leveraging the combination of several of its core technologies:

• Antibody Discovery: Unlocking Access to Difficult Membrane Proteins. Through its subsidiary Cell Surface Bio, the company is generating antibodies against challenging membrane proteins where others have been unsuccessful, opening new avenues for drug discovery against hard-to-treat diseases.
  
  
• Lead Optimization: Engineering Better Antibodies. Paratope-PLUS^® combines CDR-Scanning technology with AI-assisted antibody engineering to identify antibody variants with improved properties, enabling the development of better therapeutics and new intellectual property.
  
  
• Specificity Testing: Off-Target Screening for Lead Selection and IND Enablement. The Membrane Proteome Array™ (MPA) identifies unintended off-target antibody binding to human proteins, helping the industry develop safer therapeutic candidates, avoid clinical failure, and support regulatory submissions.

25 Years of Innovation and Growth

Founded in 2001 by Drs. Benjamin Doranz, Joseph Rucker, and Sharon Willis, Integral Molecular began in the University City Science Center's incubator. The company has since evolved from developing specialized technologies and services to building its own therapeutic antibody pipeline. Its discoveries are advancing through licensing and partnerships, including CTIM-76, an out-licensed antibody now in clinical testing for solid tumors. Today, Integral Molecular is pursuing over 100 disease-associated membrane proteins that have been notoriously difficult to target, and its technologies support more than 600 biotechnology and pharmaceutical organizations worldwide.

Rooted in Philadelphia, Committed to the Community

Integral Molecular continues to expand in Philadelphia, investing in research facilities, scientific talent, and career development. Its community partnerships include the Wistar Institute, Drexel University, and the Science Center's FirstHand program. The company has been recognized as an Employer of Choice by the City of Philadelphia and a Top Workplace by The Philadelphia Inquirer.

"Philadelphia helped make Integral Molecular possible, and our people and community have been central to our success," said Sharon Willis, PhD, co-founder. "As we continue to grow, we're excited about the science ahead and the opportunities we're creating to make an impact on patients and our community."

About Integral Molecular

Integral Molecular (integralmolecular.com) is the industry leader in developing innovative technologies that advance the discovery of antibody therapeutics against difficult protein targets. With 25 years of experience focused on membrane proteins, viruses, and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

Press Contact
Integral Molecular
Soma Banik, PhD
Director of Public Relations
215-966-6061
[email protected]

SOURCE Integral Molecular